Apolipoprotein E: Receptor Binding Properties

  • K. H. Weisgraber
  • T. L. Innerarity
  • S. C. RallJr.
  • R. W. Mahley


Apolipoprotein E (apo-E) was first described in human very low density lipoproteins (VLDL)1,2 and has now been demonstrated in several lipoprotein classes in a variety of species.3 it occurs in chylomicrons and their remnants, VLDL, and a subfraction of high density lipoproteins (HDL) referred to as HDL1, HDLC, or HDL-with apo-E.3,4 The amino acid sequence of apo-E has been determined.5 The protein consists of a single polypeptide chain of 299 residues with a molecular weight of 34,000.


High Density Lipoprotein Receptor Binding High Density Lipoprotein Cyanogen Bromide Normal Human Fibroblast 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    V. G. Shore and B. Shore, Heterogeneity of human plasma very low density lipoproteins, Separation of species differing in protein components, Biochemistry 12: 502 – 507 (1973).PubMedCrossRefGoogle Scholar
  2. 2.
    F. A. Shelburne and S. H. Quarfordt, A new apoprotein of human plasma very low density lipoproteins, J. Biol. Chem. 249: 1428 – 1433 (1974).PubMedGoogle Scholar
  3. 3.
    R. W. Mahley, Alterations in plasma lipoproteins induced by cholesterol feeding in animals including man, in: “Disturbances in Lipid and Lipoprotein Metabolism, ” J. M. Dietschy, A. M. Gotto, Jr., and J. A. Ontko, eds., American Physiological Society, Bethesda, pp. 181–197 (1978).Google Scholar
  4. 4.
    K. H. Weisgraber and R. W. Mahley, Subfractionation of human high density lipoproteins by heparin-Sepharose affinity chromatography, J. Lipid Res. 21: 316 – 325 (1980).PubMedGoogle Scholar
  5. 5.
    S. C. Rail, Jr., K. H. Weisgraber. and R. W. Mahley, Human apolipoprotein E, The complete amino acid sequence, J. Biol. Chem. 257: 4171 – 4178 (1982).Google Scholar
  6. 6.
    G. Utermann, M. Hees, and A. Steinmetz, Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man, Nature 269: 604 – 607 (1977).PubMedCrossRefGoogle Scholar
  7. 7.
    V. I. Zannis and J. L. Breslow, Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and post-translational modification, Biochemistry 20: 1033 – 1041 (1981).PubMedCrossRefGoogle Scholar
  8. 8.
    K. H. Weisgraber, S. C. Rail, Jr., and R. W. Mahley, Human E apoprotein heterogeneity, Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms, J. Biol. Chem. 256: 9077 – 9083 (1981).Google Scholar
  9. 9.
    V. I. Zannis, J. L. Breslow, G. Utermann, R. W. Mahley, K. H. Weisgraber, R. J. Havel, J. L. Goldstein, M. S. Brown, G. Schonfeld, W. R. Hazzard, and C. Blum, Proposed nomenclature of apo-E isoproteins, apo-E genotypes, and phenotypes, J. Lipid Res. 23: 911 – 914 (1982).PubMedGoogle Scholar
  10. 10.
    T. L. Innerarity and R. W. Mahley, Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins, Biochemistry 17: 1440 – 1447 (1978).PubMedCrossRefGoogle Scholar
  11. 11.
    R. W. Mahley and T. L. Innerarity, Lipoprotein receptors and cholesterol homeostasis, Biochim. Biophys. Acta 737: 197 – 222 (1983).PubMedGoogle Scholar
  12. 12.
    B. C. Sherrill, T. L. Innerarity, and R. W. Mahley, Rapid hepatic clearance of the canine lipoproteins containing only the E apoprotein by a high affinity receptor, Identity with the chylomicron remnant transport process, J. Biol. Chem. 255: 1804 – 1807 (1980).PubMedGoogle Scholar
  13. 13.
    R. W. Mahley, Atherogenic hyperlipoproteinemia: the cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol, Med. Clin. North Am. 66: 375 – 402 (1982).PubMedGoogle Scholar
  14. 14.
    R. W. Mahley, Development of accelerated atherosclerosis: concepts derived from cell biology and animal model studies, Arch. Pathol. Lab. Med. 107: 393 – 399 (1983).PubMedGoogle Scholar
  15. 15.
    V. Gordon, T. L. Innerarity, and R. W. Mahley, Formation of cholesterol- and apo-E-enriched high density lipoproteins in vitro, J. Biol. Chem. 258: 6202 – 6212 (1983).PubMedGoogle Scholar
  16. 16.
    G. Utermann, M. Jaeschke, and J. Menzel, Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very low density lipoproteins, FEBS Lett. 56: 352 – 355 (1975).PubMedCrossRefGoogle Scholar
  17. 17.
    R. W. Mahley and B. Angelin, Type III hyperlipoproteinemia: recent insights into the genetic defect of familial dysbeta- lipoproteinemia, Adv. Intern. Med. 29: 385 – 411 (1984).PubMedGoogle Scholar
  18. 18.
    M. Fainaru, R. W. Mahley, R. L. Hamilton, and T. L. Innerarity, Structural and metabolic heterogeneity of &-very low density lipoproteins from cholesterol-fed dogs and from humans with type III hyperlipoproteinemia, J. Lipid Res. 23: 702 – 714 (1982).PubMedGoogle Scholar
  19. 19.
    J. L. Goldstein, Y. K. Ho, M. S. Brown, T. L. Innerarity, and R. W. Mahley, Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine 3-very low density lipoproteins, J. Biol. Chem. 255: 1839 – 1848 (1980).PubMedGoogle Scholar
  20. 20.
    R. J. Havel, Y.-S. Chao, E. E. Windier, L. Kotite, and L. S. S. Guo, Isoprotein specificity in the hepatic uptake of apolipo-protein E and the pathogenesis of familial dysbetalipoproteinemia, Proc. Natl. Acad. Sci., U.S.A., 77: 4349 – 4353 (1980)PubMedCrossRefGoogle Scholar
  21. 21.
    R. E. Gregg, L. A. Zech, E. J. Schaefer, and H. B. Brewer, Jr., Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E, Science 211: 584 – 585 (1981).PubMedCrossRefGoogle Scholar
  22. 22.
    K. H. Weisgraber, T. L. Innerarity, and R. W. Mahley, Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site, J. Biol. Chem. 257: 2518 – 2521 (1982).PubMedGoogle Scholar
  23. 23.
    W. J. Schneider, P. T. Kovanen, M. S. Brown, J. L. Goldstein, G. Utermann, W. Weber, R. J. Havel, L. Kotite, J. P. Kane, T. L. Innerarity, and R. W. Mahley, Familial dysbetalipoproteinemia, Abnormal binding of mutuant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows, J. Clin. Invest. 68: 1075 – 1085 (1981).PubMedCrossRefGoogle Scholar
  24. 24.
    S. C. Rail, Jr., K. H. Weisgraber, T. L. Innerarity, and R. W. Mahley, Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects, Proc. Natl. Acad. Sci., U.S.A., 79: 4696 – 4700 (1982).CrossRefGoogle Scholar
  25. 25.
    S. C. Rail, Jr., K. H. Weisgraber, T. L. Innerarity, T. P. Bersot, R. W. Mahley, and C. B. Blum, Identification of a new structural variant of human apolipoprotein E - E2(Lys-146 Glyn) - in a type III hyperlipoproteinemic subject with the E3/2 phenotype, J. Clin. Invest. 72: 1288 – 1297 (1983).CrossRefGoogle Scholar
  26. 26.
    S. C. Rail, Jr., unpublished observation.Google Scholar
  27. 27.
    D. Y. Hui, T. L. Innerarity, and R. W. Mahley, Defective hepatic lipoprotein receptor binding of beta-very low density lipoproteins from type III hyperlipoproteinemic patients: importance of apolipoprotein E, J. Biol. Chem. 259: 860 – 869 (1983).Google Scholar
  28. 28.
    G. Utermann, A. Steinmetz, and W. Weber, Genetic control of human apolipoprotein E polymorphism: comparison of one- and two-dimensional techniques of isoprotein analysis, Hum. Genet. 60: 344 – 351 (1982).PubMedCrossRefGoogle Scholar
  29. 29.
    R. J. Havel, Familial dysbetalipoproteinemia, Med. Clin. North Am. 66: 441 – 454 (1982).PubMedGoogle Scholar
  30. 30.
    H.-J. Menzel, R.-G. Kladetzky, and G. Assmann, Apolipoprotein E polymorphism and coronary artery disease, Arterioscleroisis 3: 310 – 315 (1983).CrossRefGoogle Scholar
  31. 31.
    S. C. Rall, Jr., K. H. Weisgraber, T. L. Innerarity, R. W. Mahley, and G. Assmann, Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia, J. Clin. Invest. 71: 1023 – 1031 (1983).PubMedCrossRefGoogle Scholar
  32. 32.
    G. Ghiselli, E. J. Schaefer, P. Gascon, and H. B. Brewer, Jr., Type III hyperlipoproteinemia associated with apolipoprotein E deficiency, Science 214: 1239 – 1241 (1981).PubMedCrossRefGoogle Scholar
  33. 33.
    G. Utermann, Apolipoprotein E: role in lipoprotein metabolism and pathophysiology of hyperlipoproteinemia type III, La Ricerca Clin. Lab. 12: 23 – 33 (1982).Google Scholar
  34. 34.
    T. L. Innerarity, E. J. Friedlander, S. C. Rail, Jr., K. H. Weisgraber, and R. W. Mahley, The receptor binding domain of human apolipoprotein E: binding of apolipoprotein E fragments, J. Biol. Chem. 258: 12341 – 12347 (1983).PubMedGoogle Scholar
  35. 35.
    K. H. Weisgraber, T. L. Innerarity, K. J. Harder, R. W. Mahley, R. W. Milne, Y. L. Marcel, and J. T. Sparrow, The receptor binding domain of human apolipoprotein E: monoclonal anti-body inhibition of binding, J. Biol. Chem. 258: 12348 – 12354 (1983).PubMedGoogle Scholar
  36. 36.
    R. W. Mahley, T. L. Innerarity, R. E. Pitas, K. H. Weisgraber, J. H. Brown, and E. Gross, Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apo-proteins, J. Biol. Chem. 252: 7279 – 7287 (1977).PubMedGoogle Scholar
  37. 37.
    K. H. Weisgraber, T. L. Innerarity, and R. W. Mahley, Role of the lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts, J. Biol. Chem. 253: 9053 – 9062 (1978).PubMedGoogle Scholar
  38. 38.
    R. W. Mahley, Apolipoprotein E and cholesterol metabolism, Klin. Wochenschr. 61: 225 – 232 (1983).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • K. H. Weisgraber
    • 1
  • T. L. Innerarity
    • 1
  • S. C. RallJr.
    • 1
  • R. W. Mahley
    • 1
  1. 1.The Gladstone Foundation Laboratories and the Departments of Pathology and MedicineUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations